Antibiotic Injectables

Product Details:

Indications:    

• Lincomycin Injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci.

Dosage:

• If significant diarrhea occurs during therapy, this antibiotic should be discontinued.

Adults:

• Serious infections – 600mg (2ml) intramuscularly every 24 hours.
• More severe infections – 600mg (2ml) intramuscularly every 12 hours or more often.
• Children over 1 month of age
• Serious infections – one intramuscular injection of 10mg/kg every 24 hours.
• More severe infection – one intramuscular injection of 10mg/kg every 12 hours or more often.

Adults:

• The intravenous dose will be determined by the severity of the infection. For serious infections doses of 600mg of lincomycin to 1 gram are given every 8-12 hours. For more severe infections these doses may have to be increased. In life-threatening situations daily intravenous doses of as much as 8 grams have been given. Intravenous doses are given on the basis of 1 gram of Lincomycin diluted in not less than 100 ml of appropriate solution and infused over a period of not less than one hour.

These doses may be repeated as often as required to the limit of the maximum recommended daily dose of 8 grams of Lincomycin.

Children over 1 month of age

• 10-20 mg/kg/day depending on the severity of the infection may be infused in divided doses as described above for adults.

Product Details:

Indications:    

• Susceptible infections
• Urinary tract infections

Dosage:

Susceptible infections

• Adult: 4-6 mg/kg once daily or in equally divided doses given every 8 or 12 hr. Life-threatening infections: Increase to up to 7.5 mg/kg daily every 8 hr. All doses may be given as IM, slow IV (over 3-5 min) or as 50-200 ml infusion over
• 0.5-2 hr. Treatment is usually given for 7-14 days.
• Child: Premature infants and neonates <1 wk: 6 mg/kg daily in divided doses every 12 hr. Infants and neonates >1 wk: 7.5-9 mg/kg daily in divided doses every 8 hr. Older children: 6-7.5 mg/kg daily in divided doses every 8 hr. Alternative regimen: Neonates <6 wk: 4-6.5 mg/kg daily in divided doses every 12 hr. Older infants and children: 5.5-8 mg/kg daily in divided doses every 8 or 12 hr.

Urinary tract infections

• Adult: 150 mg as a single daily dose for 5 days.
• Complicated UTI: 3-4 mg/kg daily in divided doses every 12 hr. All doses may begiven as IM, slow IV (over 3-5 min) or as a 50-200 ml infusion over 0.5-2 hr. Treatment is usually given for 7-14 days.

Product Details:

Indications:

• Cefpirome Sulphate Injection is a semi-synthetic cephalosporin which is intravenously administered to treat bacterial infections such as bronchopneumonia, pyelonephritis, cellulitis wound infections, septicaemia, bacteraemia, and other serious infections in intensive care patients. This antibiotic is effective in fighting off a variety of Gram positive and negative organisms, and is highly recommended for patients who have life threatening bacterial infections. The medication works by preventing bacteria from spreading further, ultimately leading to its elimination.

Dosage:

• This medication should normally be administered by a healthcare professional. Dosage will vary depending on the patient and the condition being treated. As an example, the typical dosage for patients with urinary tract infection is 1gm, 2 times a day. Dosage when treated lower respiratory tract infection may be higher, at 1gm to 2gm.

Product Details:

Indications:    

• Susceptible infections
• Prophylaxis of surgical infections
• Mild to moderate susceptible infections
• Uncomplicated gonorrhoea

Dosage:

Susceptible infections

• Adult: In terms of imipenem, 1-2 g daily in divided doses every 6-8 hr, given via IV infusion. Doses 250 or 500 mg are infused over 20-30 minutes, and doses of 750 mg or 1 g over 40-60 minutes.
• Child: >40 kg: same as adult dose. >3 mth and <40 kg: 15-25 mg/kg every 6 hr by IV infusion. Up to 90 mg/kg may be given to older children with cystic fibrosis.
• Neonates and infants <3 mth: 4 wk-3 mth, 25 mg/kg every 6 hr; 1-4 wk, 25 mg/kg every 8 hr; up to 1 wk, 25 mg/kg every 12 hr.
• Max Dosage: Adults and children >40 kg: 4 g/day or 50 mg/kg. Children <40 kg: 2 g/day.

Prophylaxis of surgical infections

• Adult: In terms of imipenem, 1 g given on induction of anaesthesia, followed by 1 g 3 hr later, with additional doses of 500 mg at 8 and 16 hr after induction if necessary.

Mild to moderate susceptible infections

• Adult: In terms of imipenem, 500 mg or 750 mg every 12 hr.

Uncomplicated gonorrhoea

• Adult: In terms of imipenem: A single 500 mg dose may be used.

Product Details:

Indications:

• Susceptible infections
• Cystic fibrosis
• Meningitis
• Skin and skin structure infections
• Intra-abdominal infections

Dosage:

Susceptible infections:

• Adult: 0.5-1 g 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min.
• Child: ≥3 mth ≤50 kg: 10 or 20 mg/kg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min.

Cystic fibrosis; Meningitis:

• Adult: 2 g 8 hrly infused over approx 15-30 min.
• Child: ≥3 mth ≤50 kg: 40 mg/kg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min. Max: 2 g.

Skin and skin structure infections:

• Adult: 500 mg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min.
• Child: ≥3 mth ≤50 kg: 10 mg/kg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min. Max: 500 mg.

Intra-abdominal infections:

• Adult: 1 g 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min.
• Child: ≥3 mth ≤50 kg: 20 mg/kg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min. Max: 1000 mg.

Product Details:

Indications:

• Bone and joint infections
• Genitourinary infections
• Gynaecological infections
• Intra-abdominal infections
• Skin and skin structure infections
• Respiratory tract infections
• Central nervous system infections

Dosage:

• Adult: 1-2 g 8-12 hrly depending on the severity of the infection. May be given via deep IM inj, slow IV inj over 3-5 min or by IV infusion over 20-60 min. Max: 12 g daily.
• Child: 0-1 wk 50 mg/kg/dose 12 hrly IV inj; >1-4 wk 50 mg/kg/dose 8 hrly IV inj; 1 mth to 12 yr <50 kg: 50-180 mg/kg IM or IV inj in 4-6 divided doses.

Product Details:

Indications:

• Acute bacterial sinusitis (adequately diagnosed)
• Acute otitis media
• Acute exacerbations of chronic bronchitis (adequately diagnosed)
• Community acquired pneumonia
• Cystitis
• Pyelonephritis
• Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.
• Bone and joint infections, in particular osteomyelitis.

Dosage:

• For adults and children ≥ 40 kg, this formulation of Co-amoxiclav provides a total daily dose of 1500 mg amoxicillin/375 mg clavulanic acid, when administered as recommended below.

Product Details:

Indications:

• Meningitis
• Gonorrhoea
• Prophylaxis of surgical infections
• Susceptible infections
• Pneumonia
• Acute exacerbations of chronic bronchitis

Dosage:

Adult:

Meningitis

• Adult: As cefuroxime Na: 3 g 8 hrly.

Gonorrhoea

• Adult: As cefuroxime Na: 1.5 g as a single dose divided between 2 inj sites. May be given w/ oral probenecid 1 g.

Prophylaxis of surgical infections

• Adult: 1.5 g IV before the procedure followed by 750 mg IM 8 hrly for up to 24-48 hr depending on the procedure. For total joint replacement: 1.5 g, may be mixed w/ methylmethacrylate cement.

Susceptible infections

• Adult: As cefuroxime Na: 0.75 g 8 hrly, by deep IM or slow IV inj over 3-5 min or IV infusion, may increase up to 1.5 g 6-8 hrly in more severe infections.

Pneumonia

• Adult: 1.5 g bid by deep IM or slow IV inj over 3-5 min or IV infusion, followed by an oral dose 0.5 g bid.

Acute exacerbations of chronic bronchitis

• Adult: 750 mg bid by deep IM or slow IV inj over 3-5 min or IV infusion, followed by an oral dose 500 mg bid.

Child:

Meningitis, Susceptible infections, Pneumonia, Acute exacerbations of chronic bronchitis:

• Child: ≤3 wk 30-100 mg/kg daily by IV inj given as 2 or 3 divided doses; >3 wk <40 kg: 30-100 mg/kg daily by IV inj given as 3 or 4 divided doses; 60 mg/kg daily to most infections.

Product Details:

Indications:

• Early syphilis, late syphilis or syphilis of unknown duration
• Congenital syphilis (absence of clinical signs in the neonate and adequate treatment in the mother)
• Streptococcal tonsillitis, endemic treponematoses (bejel, yaws, pinta)
• Prophylaxis of diphtheria in the event of direct contact
• Primary and secondary prophylaxis of rheumatic fever

Dosage:

Syphilis:

• Child: 50 000 IU (37.5 mg)/kg/injection (max. 2.4 MIU or 1.8 g/injection)
• Adult: 2.4 MIU (1.8 g)/injection

Streptococcal tonsillitis, bejel, yaws, pinta, prophylaxis of diphtheria, prophylaxis of rheumatic fever:

• Child under 30 kg: 600 000 IU (450 mg)/injection
• Child 30 kg and over and adult: 1.2 IU (900 mg)/injection

Product Details:

Indications:

• Respiratory tract infections
• Skin & skin structure infection
• Abdominal infections
• Urinary Tract Infections
• Empiric therapy for febrile neutropenic patients

Dosage:

For Pseudomonas aeruginosa, use 2 g IV every 8 hours. or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently.
IM route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli when the IM route is considered to be a more appropriate route of drug administration
When only serum creatinine is available, the following formula (Cockcroft and Gauit equation) 3 may be used to estimate creatinine. The serum creatinine should represent a steady state of renal function:

Male: Creatinine clearance (mL/min)=Weight(kg)x(140age)72 x serum creatinine (mg/dL)

Female: 0.85 x above value.

Product Details:

Indications:

• Genitourinary infections
• Lower respiratory tract infections
• Mild to moderate infections
• Moderate to severe infections
• Life-threatening infections

Dosage:

• Genitourinary infections, Lower respiratory tract infections
• Adult: Mild to moderate infections: 1/0.5 g to 2/1 g of cefotaxime/sulbactam every 8-12 hrs. Moderate to severe infections: 1/0.5 g to 2/1 g of cefotaxime/sulbactam every 6-8 hrs. Max (sulbactam): 4 g.
• Child: 100/50 mg to 150/75 mg of cefotaxime/sulbactam /kg/day in 3 divided doses. Life-threatening infections: Dose of cefotaxime may be increased up to 12 g/day.
• Max Dosage: Max (sulbactam): Sulbactam: Adult: 4 g. Child: 80 mg/kg/day in divided doses.

Product Details:

Indications:

• Intra abdominal infections
• Skin and soft tissue infection
• Surgical infections
• Infections of the respiratory tract
• Bacterial infection of the respiratory tract
• Infections of the urinary tract
• Respiratory tract infections

Dosage:

• The usual adult daily dose of sterile cefoperazone is 2 to 4 grams per day administered in equally divided doses every 12 hours.
• In severe infections or infections caused by less sensitive organisms, the total daily dose and/or frequency may be increased. Patients have been successfully treated with a total daily dosage of 6–12 grams divided into 2, 3 or 4 administrations ranging from 1.5 to 4 grams per dose.

Product Details:

Indications:

• Susceptible infections including septicemia, pneumonia, skin and skin structure, bone and joint, gynecologic, intraabdominal, meningitis, urinary tract.

Dosage:
 
Adult:

• Uncomplicated pneumonia, mild skin or skin structure: 500mg–1g IV or IM every 8hrs. Bone and joint: 2g IV every 12hrs. Serious gynecologic, intraabdominal, meningitis, or very severe life-threatening (esp. immunocompromised): 2g IV every 8hrs. Lung infections by Pseudomonas in cystic fibrosis: 30–50mg/kg IV every 8hrs (max 6g/day). Renal impairment: CrCl 31–50mL/min: 1g every 12hrs; CrCl 16–30mL/min: 1g every 24hrs; CrCl 6–15mL/min: 500mg every 24hrs; CrCl <5mL/min: 500mg every 48hrs. Hemodialysis: 1g loading dose then 1g after dialysis session. Peritoneal dialysis: 1g loading dose then 500mg every 24hrs.

Product Details:

Indications:    

• Bacteriological studies to determine the causative organism should be performed and its susceptibility to Clindamycin tested. It is indicated in the treatment of infections caused by susceptible strains of:
• Staph. aureus: abscesses, bacteremia, endocarditis, pneumonia and osteomyelitis, but not in meningitis or in methicillin resistant organisms.
• Streptococcus (anaerobic species): bacteremia, endocarditis, abscesses and upper respiratory infections (sinusitis).
• Strep. pneumoniae: pneumonia, endocarditis, arthritis and upper respiratory infections.
• Clostridium perfringens: gas gangrene.
• Campylobacter jejuni: enteritis.
• Bacteroides species: oral disease, upper respiratory tract infections and lung abscess.
• Fusobacterium nucleatum: ulcerative pharyngitis, lung abscess, empyema, genital infections, gingivitis.

Dosage:

• Clindamycin ampoules are not for multiple dosing and any unused portion must be discarded.

Adults:

• Moderate to severe infections: 600 to 1200 mg/day in 2, 3 or 4 equal divided doses.
• Severe infections: 1200 to 2700 mg/day in 2, 3 or 4 equal doses.

Children:

• Over the age of 1 month.
• 15 to 40 mg/kg body mass daily in divided doses.
• In severe infections: Not less than 300 mg daily (irrespective of body mass)

Neonates:

• Safety and appropriate dosages in infants less than one month old have not been established.

Clindamycin may be administered in the form of a single rapid infusion of the initial dose followed by continuous IV infusion. This will maintain the serum levels of Clindamycin at the following levels:

Product Details:

Indications:

• Complicated & uncomplicated UTI, moderate to severe pneumonia, complicated intra abdominal infections, febrile neutropenia, serious skin & skin structure infections, bacterial septicemia, post operative infections.

Dosage:

Adult:

• IM/IV Susceptible infections Mild to moderate: 1-2 g/day in 2 divided doses.
• Severe: up to 4 g/day in 2 divided doses.
• Empirical therapy for febrile neutropenia up to 6g/day in 3 divided doses.

Product Details:

Indications:

• Meningitis
• Respiratory tract infections
• Skin and soft tissue infections
• Intra-abdominal infections
• Urinary tract infections
• Septicaemia
• Bone and joint infections
• Gynaecological infections

Dosage:

Intravenous

• Adult: Ratio of sulbactam:cefoperazone is 1:1. Doses are expressed in terms of cefoperazone.
• Mild to moderate infections: 1-2 g daily, given in equally divided doses every 12 hours.
• Severe infections: Up to 4 g daily, given in equally divided doses every 12 hours; max dose of sulbactam: 4 g daily.
• Child: Ratio of sulbactam:cefoperaone is 1:1. Doses are expressed in terms of cefoperazone.
• Recommended doses: 20-40 mg/kg/day, given in equally divided doses every 6-12 hours.
• For serious infections: Up to 160 mg/kg/day, given in 2-4 equally divided doses may be used.
• Max dose of sulbactam: 80 mg/kg/day
• Renal impairment: Dose adjustments may be needed.

Reconstitution

• For IV infusion, each vial should be reconstituted with suitable amount of sterile water for injection, normal saline, 5% dextrose in water, and then diluted to 20 ml using the same diluent followed by admin over 15-60 minutes. For IV injection, each vial should be reconstituted as above and given over at least 3 minutes.

Product Details:

Indications:

• Gynecological infections,
• Urinary tract infections, and
• Post-operative infections

Dosage:

• The usual adult daily dose is 2-4 g in two divided dosing depending on the type and severity of the infection

Product Details:

COMPOSITION- Ceftriaxone Injection 1gm

PACKING- 1 Vial

MRP- 60/- Per Vial

Additional Information:

• Packaging Details: 1 Vial

Product Details:

COMPOSITION- Piperacillin & Tazobactam for Injection 4.5 gm


PACKING- 1 Vial


MRP- 490/- Per Vial

Additional Information:

• Packaging Details: 1 Vial

Product Details:

Indications:

• Renal  and  urinary  tract  infections;  Lower  respiratory  tract  infections,  particularly  pneumonia;  Gonococcal  infections; Skin and soft tissue, bone and joint infections; Bacterial meningitis; Serious bacterial infections e.g. septicemia; ENT infections; Typhoid fever; Infections in cancer patients; Prevention of post-operative infection; Pre-operative prophylaxis of infections associated with surgery.

Dosage:

• IM Injection: 250 mg or 500 mg Ceftriaxone should be dissolved with 2 ml of 1% Lidocaine Injection or 1 g with 3.5ml of 1% Lidocaine injection. The solution should be administered by deep intramuscular injection. Dosage greater than 1 g should be divided and injected at more than one site. Solution on Lidocaine should not be administered intravenously.
• IV Injection: 250 mg or 500 mg Ceftriaxone should be dissolved with 5 ml of Water for Injection, 1 g with 10 ml of Water for Injection & 2 g with 20 ml Water for Injection. The solution should be administered over 2-4 minutes, directly into the vein or via the tubing of an intravenous infusion

Product Details:

Indications:    

• Nosocomial pneumonia
• Empiric therapy for febrile neutropenic patients
• Complicated intra-abdominal infections
• Complicated intra-abdominal infections
• Skin and soft tissue infections

Dosage:
Nosocomial pneumonia; Empiric therapy for febrile neutropenic patients:

• Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 6 hrly for 5-14 days by infusion over 30 min.
• Child: 2-12 yr 90 mg/kg (piperacillin 80 mg/kg and tazobactam 10 mg/kg) 6 hrly for 5-14 days by infusion over 30 min. Max: 4.5 g per dose; >12 yr Same as adult dose.

Complicated intra-abdominal infections

• Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 8 hrly for 5-14 days by infusion over 30 min.
• Child: 2-12 yr 112.5 mg/kg (piperacillin 100 mg and tazobactam 12.5 mg) 8 hrly for 5-14 days by infusion over 30 min. Max: 4.5 g per dose.

Complicated urinary tract infections; Skin and soft tissue infections:

• Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 8 hrly for 5-14 days by infusion over 30 min.

Product Details:

Indications:    

• Complicated intra-abdominal infections
• Complicated skin and skin structure infections
• Community-acquired pneumonia

Dosage:

Complicated intra-abdominal infections; Complicated skin and skin structure infections:

• Adult: Initially, 100 mg as a single dose, followed by 50 mg 12 hrly for 5-14 days.
• Infuse dose over 30-60 min.

Community-acquired pneumonia:

• Adult: Initially, 100 mg as a single dose followed by 50 mg 12 hrly for 7-14 days. Infuse dose over 30-60 min.

Product Details:

Indications:    

• Severe Gram-positive infections
• Prophylaxis of Gram-positive infection in high-risk patients undergoing surgery
• Continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis

Dosage:

Severe Gram-positive infections:

• Adult: Initially, 6 mg/kg on first day, followed by 3 mg/kg/day. Severe infection: 6 mg/kg every 12 hr for the 1st 3 doses followed by 6 mg/kg/day. Doses may be given via IM inj, IV bolus or IV infusion over 30 minutes.
• Child: Loading dose: 10 mg/kg every 12 hr for 3 doses followed by 6-10 mg/kg/day depending on severity of the infection. Neonates: Loading dose: 16 mg/kg on the 1st day, followed by maintenance doses of 8 mg/kg/day by IV infusion.

Prophylaxis of Gram-positive infection in high-risk patients undergoing surgery:

• Adult: 400 mg as single dose at induction of anesth.
• Incompatibility: Incompatible with aminoglycosides and should not be mixed before injection.

Continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis:

• Adult: If the patient is febrile, an initial loading dose of 400 mg may be given. Teicoplanin is added to the dialysis solution at a concentration of 20 mg/litre; dose is added into each bag of solution in the first wk, followed by alternate bags in the second wk and then in the overnight dwell bag in the third wk. 

Product Details:

Indications:

• Renal  and  urinary  tract  infections;  Lower  respiratory  tract  infections,  particularly  pneumonia;  Gonococcal  infections; Skin and soft tissue, bone and joint infections; Bacterial meningitis; Serious bacterial infections e.g.septicemia; ENT infections; Typhoid fever; Infections in cancer patients; Prevention of post-operative infection;Pre-operative prophylaxis of infections associated with surgery.

Dosage:

• IM Injection: 250 mg or 500 mg Ceftriaxone should be dissolved with 2 ml of 1% Lidocaine injection or 1 g with 3.5ml of 1% Lidocaine injection. The solution should be administered by deep intramuscular injection. Dosage greater than 1 g should be divided and injected at more than one site. Solution on Lidocaine should not be administered intravenously.
• IV Injection: 250 mg or 500 mg Ceftriaxone should be dissolved with 5 ml of Water for Injection, 1 g with 10 ml of Water for Injection & 2 g with 20 ml Water for Injection. The solution should be administered over 2-4 minutes, directly into the vein or via the tubing of an intravenous infusion

Product Details:

Indications:    

• Bone and joint infections.
• Gastrointestinal infections.
• Lower respiratory tract infections.
• Skin and soft tissue infections.
• Central nervous system infections.
• Mild to moderate urinary tract infections.

Dosage:

Bone and joint infections; Gastrointestinal infections; Lower respiratory tract infections; Skin and soft tissue infections; Central nervous system infections:

• Adult: As tobramycin sulfate: 3-5 mg/kg daily in 3 or 4 divided doses, by IM inj or IV infusion over 20-60 min. Usual treatment duration: 7-10 days.
• Child: As tobramycin sulfate: 6-7.5 mg/kg daily in 3 or 4 divided doses. For premature or full-term neonates, doses up to 4 mg/kg daily in 2 equal doses may be given. Usual treatment duration: 7-10 days.

Mild to moderate urinary tract infections:

• Adult: As tobramycin sulfate: 2-3 mg/kg as a single dose.

Product Details:

Indications:

• Pseudomonal lung infections in cystic fibrosis    
• Prophylaxis of surgical infection in patients undergoing prostate surgery
• Bone and joint infection
• Skin and skin structure infections, complicated
• Complicated intra-abdominal infections   
• Bacterial meningitis
• Nosocomial pneumonia   
• Empiric therapy for febrile neutropenic patients
• Complicated urinary tract infections   

Dosage:

Pseudomonal lung infections in cystic fibrosis:

• Adult: 100-150 mg/kg 8 hrly as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min. Max: 9 g daily.
• Child: <40 kg: 150 mg/kg daily in 3 divided doses. Max: 6 g daily.
• Elderly: >80 yr Max: 3 g daily.

Prophylaxis of surgical infection in patients undergoing prostate surgery:

• Adult: 1 g at induction of anaesth repeated if necessary upon removal of catheter. It is given as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min.
• Elderly: >80 yr Max: 3 g daily.

Bone and joint infections, Skin and skin structure infections, Complicated intra-abdominal infections:

• Adult: 1-2 g 8 hrly as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min.
• Child: <40 kg: 100-150 mg/kg daily in 3 divided doses. Max: 6 g daily.
• Elderly: >80 yr Max: 3 g daily.

Bacterial meningitis, Nosocomial pneumonia, Empiric therapy for febrile neutropenic patients:

• Adult: 2 g 8 hrly as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min.
• Child: <40 kg: 150 mg/kg daily in 3 divided doses. Max: 6 g daily.
• Elderly: >80 yr Max: 3 g daily.

Complicated urinary tract infections:

• Adult: 1-2 g 8-12 hrly as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min.
• Child: <40 kg: 100-150 mg/kg daily in 3 divided doses. Max: 6 g daily.
• Elderly: >80 yr Max: 3 g daily.

Product Details:

Indications:

• Susceptible infections
• Meningitis

Dosage: 

Susceptible infections

• Adult: 15,000-25,000 U/kg daily by continuous IV drip or intermittent infusion 12 hrly at 60-120 min duration. Max: 2,000,000 U/day.
• Child: <2 yr 40,000 U/kg daily in divided doses 12 hrly; ≥2 yr Same as adult dose.
• Adult: 25,000-30,000 U/kg daily in divided doses 4-6 hrly. Max: 2,000,000 U/day.
• Child: <2 yr 40,000 U/kg daily in divided doses 6 hrly (not routinely recommended due to pain at injection sites); ≥2 yr Same as adult dose but not routinely recommended due to pain at injection sites.

Meningitis

• Adult: 50,000 U once daily for 3-4 days, then on alternate days for at least 2 wk after CSF cultures are negative and CSF glucose content is normal. Max: 2,000,000 U/day.
• Child: <2 yr 20,000 U once daily for 3-4 days or 25,000 U on alternate days, followed by the latter dose for at least 2 wk after CSF cultures are negative and CSF glucose content is normal; ≥2 yr Same as adult dose.

Product Details:

Indications:

• Uncomplicated gonorrhoea
• Susceptible infections
• Prophylaxis of surgical infections

Dosage:

Uncomplicated gonorrhea:

• Adult: 250 mg as a single dose.

Susceptible infections:

• Adult: 1 g once daily via deep IM inj or slow IV inj over at least 2-4 min, intermittent IV infusion over at least 30 min, increased to 2-4 g daily as a single dose in severe infections.
• Child: ≤12 yr 20-50 mg/kg once daily increased to 80 mg/kg in severe infections. Doses ≥50 mg/kg should be given as IV infusion over at least 30 min. Max: 50 mg/kg daily via IV infusion over 60 min (neonates).

Prophylaxis of surgical infections:

• Adult: 1 g as a single dose given 0.5-2 hr prior to surgery via deep IM inj or slow IV inj over at least 2-4 min, intermittent IV infusion over at least 30 min. Colorectal surgery: 2 g.

Product Details:

Indications:              

• Bacterial meningitis     
• Bone and joint infections
• Community-acquired pneumonia   
• Intra-abdominal infections
• Lower respiratory tract infections   
• Pelvic inflammatory disease
• Uncomplicated gonorrhoea   
• Skin and skin structure infections
• Bacterial septicaemia   
• Urinary tract infections

Dosage:

• Adult: Expressed in terms of ceftriazone/tazobactam: 1000/125 mg once daily or in equally divided doses twice a day. Total daily dose should not exceed 4 g of ceftriaxone. Continue treatment for at least 2 days after the signs and symptoms have resolved. Usual duration: 7-14 days; longer treatment may be needed in more serious infections. For Streptococci pyogenes infections, treatment should continue for at least 10 days.

Child: Expressed in terms of ceftriaxone: Serious infections: 50-75 mg/kg/day, given in divided doses every 12 hr. Total daily dose should not exceed 2 g of ceftriaxone. Continue treatment for at least 2 days after the sig ns and symptoms have resolved. Usual duration: 7-14 days; longer treatment may be needed in more serious infections. For Streptococci pyogenes infections, treatment should continue for at least 10 days.

Product Details:

Indications:    

• Clarithromycin IV 500 mg is indicated in adults and children 12 years and older.
• Clarithromycin IV 500 mg is indicated whenever parenteral therapy is required for treatment of infections caused by susceptible organisms in the following conditions;
• Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia.
• Upper respiratory tract infections for example, sinusitis and pharyngitis.
• Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelasConsideration should be given to official guidance on the appropriate use of antibacterial agents.

Dosage:

• For intravenous administration only.
• Intravenous therapy may be given for 2 to 5 days in the very ill patient and should be changed to oral Clarithromycin therapy whenever possible as determined by the physician.
• Adults: The recommended dosage of Clarithromycin IV 500 mg is 1.0 gram daily, divided into two 500mg doses, appropriately diluted as described below.
• Children older than 12 years: As for adults.
• Children under 12 years: Use of Clarithromycin IV 500 mg is not recommended for children younger than 12 years. Use Clarithromycin Paediatric Suspension.
• Elderly: As for adults.
• Renal Impairment: In patients with renal impairment who have creatinine clearance less than 30ml/min, the dosage of clarithromycin should be reduced to one half of the normal recommended dose.

Product Details:

Indications:

• Amikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. Amikacin sulfate injection is effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post operative infections (including post vascular surgery).
• Amikacin is also effective in serious complicated and recurrent urinary tract infections due to Gram-negative organisms.
• Amikacin is also effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as severe infections where the causative organism may be either a Gram-negative bacterium or staphylococcus, infections due to susceptible strains of staphylococcal/Gram-negative infections.
• In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci.

Dosage:

Adults and Children over 12 years:

• 15 mg/kg/day

Children 4 weeks to 12 years:

• 15-20 mg/kg/day.

Neonates:

• 10 mg/kg followed by 7.5 mg/kg q 12 h.

Premature Infants:

• 7.5 mg/kg in every 12 hours.

Intravenous administration:

• The solution is administered to adults over a 30 to 60 minute period.

Specific recommendation for intravenous administration:

• In paediatric patients the amount of diluents used will depend on the amount of amikacin tolerated by the patient. The solution should normally be infused over a 30 to 60 minute period. Infants should receive a 1 to 2 hour infusion.

Elderly:

• Amikacin is excreted by the renal route, renal function should be assessed whenever possible and dosage adjusted as described under impaired renal function.

Life-threatening infections and/or those caused by pseudomonas:

• The adult dose may be increased to 500 mg every eight hours.

Urinary tract infections: (other than pseudomonas infections):

• 7.5 mg/kg/day in two equally divided.

Product Details:

Indications:

• 1-Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli*, Klebsiella spp.* (including K. pneumoniae*), Proteus mirabilis*, Bacteroides fragilis*, Enterobacter spp.*, and Acinetobacter calcoaceticus*.
• 2-Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiellaspp. (including K. pneumoniae*), Bacteroides spp. (including B. fragilis), and Enterobacter spp.*
• 3-Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli*, and Bacteroides spp.* (including B. fragilis*).

Dosage:

• The recommended adult dosage of Ampicillin and Sulbactam for injection is 1.5 grams to 3 grams every six hours. The total dose of sulbactam should not exceed 4 grams per day.

Product Details:

Indications:

• Pneumonia
• Febrile Neutopenia
• Skin & skin structure infection
• Intra-abdominal infections
• Urinary Tract Infections

Dosage:

For Urinary tract infections (Adults):

• Consider administration of 0.5 – 1.0 g every 12 hours for 7-10 days. The drug can be administered as slow IV injections over 5 minutes or as an infusion for 30 minutes.

For Urinary tract infections (Pediatrics):

• For children 2 months to 16 years (≤40 kg) consider administration of 50 mg/kg of Cefepime + Tazobactam every 12 hours for 30 minutes. The injection can be given as deep intramuscular injection for mild to moderate forms of UTI.
• Intravenous

As an empirical treatment for febrile neutropenia (Adults):

• Consider administration of 2 g of Cefepime + Tazobactam every 8 hours for seven days or as needed. Cefepime + Tazobactam can be injected as slow IV over five minutes or as an infusion over 30 minutes.

As an empirical treatment for febrile neutropenia (Pediatrics):

• For children 2 months to 16 years (≤40 kg) consider administration of 50 mg/kg of Cefepime + Tazobactam every 8 hours for 7 days. Cefepime + Tazobactam can be injected as slow IV over five minutes or as an infusion over 30 minutes.

For treatment of moderate to severe pneumonia (Adults):

• Consider administration of 1-2 g of Cefepime + Tazobactam every 12 hours for ten days. Cefepime + Tazobactam can be injected as slow IV over five minutes or as an infusion over 30 minutes.

For treatment of moderate to severe pneumonia (Pediatrics):

• For children 2 months to 16 years (≤40 kg) consider administration of 50 mg/kg of Cefepime + Tazobactam every 12 hours for 10 days. Cefepime + Tazobactam can be injected as slow IV over five minutes or as an infusion over 30 minutes.

For treatment of complicated intra-abdominal infections (Adults):

• Consider administration of 2 g of Cefepime + Tazobactam every 12 hours for seven to ten days as a combined therapy with Metronidazole. Cefepime + Tazobactam can be injected as slow IV over five minutes or as an infusion over 30 minutes.

For treatment of uncomplicated skin and skin structure infections (Adults):

• Consider administration of 2 g of Cefepime + Tazobactam every 12 hours for ten days. Cefepime + Tazobactam can be injected as slow IV over five minutes or as an infusion over 30 minutes.

For treatment of uncomplicated skin and skin structure infections (Pediatrics):

• For children 2 months to 16 years (≤40 kg) consider administration of 50 mg/kg of Cefepime + Tazobactam every 12 hours for 10 days. Cefepime + Tazobactam

Product Details:

Indications:              

• Nosocomial Infections & Surgical prophylaxis
• Meningitis
• Skin & Soft tissue infections
• Chronic Suppurative Bacterial otitis media
• Cholecystitis
• Osteomyelitis
• STD
• UTI
• Infections in dialysis unit

Dosage:

• Adult Dosage: 1.5 g (1 g Ceftriazone + 0.5 g sulbactam) to 3 g (2 x 1.5 gm injection) every six hours. The total dose of sulbactam should not exceed 4 grams per day.
• Neonates, Infants And Children Up To 12 Years: Once daily administration –
• Neonates (up to 14 days): 20 to 50 mg / kg bodyweight OD (not necessary to differentiate between premature and term infants.) Infants and children (15 days to 12 years): 20 to 80 mg/kg OD.

Product Details:

Indications:

• Pseudomonal lung infections in cystic fibrosis
• Prophylaxis of surgical infection in patients undergoing prostate surgery
• Bone and joint infections
• Skin and skin structure infections, complicated
• Complicated intra-abdominal infections
• Bacterial meningitis
• Nosocomial pneumonia
• Empiric therapy for febrile neutropenic patients
• Complicated urinary tract infections

Dosage:

• Pseudomonal lung infections in cystic fibrosis: Adult: 100-150 mg/kg 8 hrly as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min. Max: 9 g daily.
• Child: <40 kg: 150 mg/kg daily in 3 divided doses. Max: 6 g daily.
• Elderly: >80 yr Max: 3 g daily.

Prophylaxis of surgical infection in patients undergoing prostate surgery:

• Adult: 1 g at induction of anaesth repeated if necessary upon removal of catheter. It is given as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min.
• Elderly: >80 yr Max: 3 g daily.
• Bone and joint infections, Skin and skin structure infections,
• Complicated intra-abdominal infections: Adult: 1-2 g 8 hrly as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min.
• Child: <40 kg: 100-150 mg/kg daily in 3 divided doses. Max: 6 g daily.
• Elderly: >80 yr Max: 3 g daily.

Bacterial meningitis, Nosocomial pneumonia, Empiric therapy for febrile neutropenic patients:

• Adult: 2 g 8 hrly as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min.Child: <40 kg: 150 mg/kg daily in 3 divided doses. Max: 6 g daily.
• Elderly: >80 yr Max: 3 g daily.
• Complicated urinary tract infections: Adult: 1-2 g 8-12 hrly as deep IM inj, slow IV inj over 3-5 min or IV infusion for up to 30 min.
• Child: <40 kg: 100-150 mg/kg daily in 3 divided doses. Max: 6 g daily.
• Elderly: >80 yr Max: 3 g daily.

Product Details:

Indications:    

• Intra-abdominal infections
• Lower respiratory tract infections
• Peritonitis
• Septicaemia
• Skin infections
• Urinary tract infections
• Endometritis
• Gynaecological infections

Dosage:

• Intra-abdominal infections; Lower respiratory tract infections; Peritonitis; Septicaemia; Skin infections; Urinary tract infections; Endometritis; Gynaecological

Infections:

• Adult: >60kg: 3.1g (3 g of ticarcillin and 100 mg of clavulanic acid) as IV infusion over 30 min every 4-6 hr continued for at least 48 hr after manifestations of infection have subsided. Therapy may be 5-7 days for intra-abdominal infections; 10-14 days for peritonitis. < 60 kg: As fixed dose combination, 200-300 mg ticarcillin/kg daily.
• Child: 3 mth-16 yr< 60 kg: 200 mg/kg of ticarcillin daily every 6 hr for mild to moderate infections; 300 mg/kg ticarcillin daily every 4 hr for severe infections. 3 mth-16 yr > 60 kg: 3.1 g (3 g of ticarcillin and 100 mg of clavulanic acid) every 6 hr for mild to moderate to every 4 hr for severe infections. 

Endometritis; Gynaecological infections

• Adult: As fixed dose combinations: Moderate infection: 200 mg ticarcillin/kg daily; severe infections: 300 mg ticarcillin/kg daily.

Product Details:

Indications:

• Intra-abdominal infections
• Urinary Tract Infections
• Septicemia
• Lower Respiratory Tract Infections
• Skin & soft tissue infections
• Bone & Joint infections

Dosage:

• Adult: 500 mg to 2g every 8 or 12 hrs.
• Maximum Dose: 8g/day.
• Pediatric: 30“90 mg/kg every 6 8 hrs.
• Maximum Dose: 120 mg/ kg/day.
• Renally Impaired Patients: After an initial loading dose of 1 to 2 grams, the dose should be halved in patients with estimated creatinine clearance between 10 and 30 mL/min.

Product Details:

Indications:
Amoxicillin sodium + clavulanate potassium is used in adults and children to treat the following infections:

• Severe ear, nose and throat infections, respiratory tract infections, urinary tract infections skin and soft tissue infections, including dental infections bone and joint infections intra-abdominal infection genital organ infections in women.

Dosage:

The usual dose is as follows, depending on the type of infection and its severity:

• Children 0-3 months: 30 mg/kg amoxicillin sodium + clavulanate potassium every 12 hours in infants < 4 kg and 30 mg/kg amoxicillin sodium + clavulanate potassium every 8 hours in infants >4 kg;
• Children 3 months – 12 years: usually 30 mg/kg amoxicillin sodium + clavulanate potassium 8 hourly;
• Adults and children 40 kg and over: usually 1.2 g 8 hourly;
• Dosage for surgical prophylaxis: procedures in adults lasting for less than 1 hour – 1.2 g amoxicillin sodium + clavulanate potassium Intravenously. Longer operations require subsequent doses of 1.2 g amoxicillin sodium + clavulanate potassium IV (up to 4 doses in 24 hours).

Product Details:

Indications:

• Acute bacterial sinusitis (adequately diagnosed)   
• Acute otitis media
• Acute exacerbations of chronic bronchitis (adequately diagnosed)   
• Community acquired pneumonia
• Cystitis   
• Pyelonephritis
• Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.   
• Bone and joint infections, in particular osteomyelitis.

Dosage:

• The usual recommended daily dosage is:
• 25/3.6 mg/kg/day in mild to moderate infections (upper respiratory tract infections e.g. recurrent tonsillitis, lower respiratory infections and skin and soft tissue infections)
• 45/6.4 mg/kg/day for the treatment of more serious infections (upper respiratory tract infections e.g. otitis media and sinusitis, lower respiratory tract infections e.g. bronchopneumonia and urinary tract infections)
• Children aged 2 months to 2 years
• Children under 2 years should be dosed according to body weight.
• Administration To minimise potential gastrointestinal intolerance, administer at the start of a meal. The absorption of FLO-CLAV is optimized when taken at the start of a meal.
• Duration of therapy should be appropriate to the indication and should not exceed 14 days without review. Therapy can be started parenterally and continued with an oral preparation.

Product Details:

COMPOSITION- Meropenem for Injection 1gm


PACKING- 1 Vial


MRP- 2300/- Per Vial

Additional Information:

• Packaging Details: 1 Vial